The Parkwalk-managed University of Bristol Enterprise Fund has joined parent IP Group to become an investor in macular degeneration-focused spinout Exonate.

Exonate, a UK-based macular degeneration medication developer based on research from the universities of Bristol and Nottingham, has obtained an unspecified sum from the University of Bristol Enterprise Fund (UBEF) II.
UBEF II is a co-investment vehicle managed by Parkwalk Advisors, the fund management arm of commercialisation firm IP Group.
Founded in 2013, Exonate is working on a form of protein known as a vascular endothelial growth factor that could tackle angiogenic diseases such as age-related macular degeneration…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?